Patented biomarker for cardiac injury. 

Biological variation of cardiac myosin-binding protein C in healthy individuals

Abstract

Objectives

Cardiac myosin-binding protein C (cMyC) is a novel biomarker of myocardial injury, with a promising role in the triage and risk stratification of patients presenting with acute cardiac disease. In this study, we assess the weekly biological variation of cMyC, to examine its potential in monitoring chronic myocardial injury, and to suggest analytical quality specification for routine use of the test in clinical practice.

Conclusion

cMyC exhibits acceptable RCV and low II suggesting that it could be suitable for disease monitoring, risk stratification and prognostication if measured serially. Analytical quality specifications based on biological variation are similar to those for cardiac troponin and should be achievable at clinically relevant concentrations.
cMyC (Cardiac Myosin-binding protein C)
cMyC (Cardiac Myosin-binding protein C)